Zomig Nasal Spray
Generic name:zolmitriptan
Dosage form: nasal spray, metered
Medically reviewed by Drugs.com. Last updated on Apr 21, 2022.
On This Page
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Drug Interactions
- Use In Specific Populations
- Overdosage
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- How Supplied/Storage and Handling
- Patient Counseling Information
Indications and Usage for Zomig Nasal Spray
Zomig Nasal Spray is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older.
Limitations of Use
- •
- Only use ZOMIG if a clear diagnosis of migraine has been established. If a patient has no response to ZOMIG treatment for the first migraine attack, reconsider the diagnosis of migraine before ZOMIG is administered to treat any subsequent attacks.
- •
- ZOMIG is not indicated for the prevention of migraine attacks.
- •
- Safety and effectiveness of ZOMIG have not been established for cluster headache.
- •
- Not recommended in patients with moderate or severe hepatic impairment [seeDosage and Administration (2.2)].
Zomig Nasal Spray Dosage and Administration
Dosing Information
The recommended starting dose for Zomig Nasal Spray in adult and pediatric patients 12 years of age and older is 2.5 mg. As the individual response to Zomig Nasal Spray may vary, the dose should be adjusted on an individual basis. The maximum recommended single dose of ZOMIG is 5 mg.
If the migraine has not resolved by 2 hours after taking ZOMIG, or returns after a transient improvement, another dose may be administered at least 2 hours after the previous dose.
The maximum daily dose should not exceed 10 mg in any 24‑hour period.
The safety of ZOMIG in the treatment of an average of more than four headaches in a 30‑day period has not been established.
Dosing in Patients with Hepatic Impairment
Zomig Nasal Spray is not recommended in patients w...